The Expanded Syringe Access Demonstration Program (ESAP), which was intended to increase access to syringes for injection drug users (IDUs), went into effect in New York State on 1 January 2001. ESAP allowed prescription-authorized health care providers to register to distribute syringes without a prescription. In spring 2002, we conducted a random postal survey of 1100 providers in New York City to evaluate involvement in ESAP and willingness to furnish IDUs with syringes. Among 363 nurse practitioners, physicians, and physician assistants responding, 16.9% knew about ESAP, and 2.0% believed they were registered; 50.5% would consider distributing syringes to patients who were IDUs. Most of those unwilling to distribute syringes were concerned about legal and moral issues. More respondents agreed that providers should prescribe syringes than distribute syringes (41.1% vs. 22.7%;
injection drug use [3] . The prevalence of hepatitis C among IDUs is estimated to be 40%-85% [4] , and the incidence among IDUs in NYC is 9.3-34.0 cases per 100,000 persons [5] .
Syringe exchange programs have proved effective in reducing injection-related HIV risks. A 1996 analysis of 3 studies in NYC ( ) found that the incidence of HIV infection was 13-n p 1442 fold lower among participants at syringe exchange programs than among nonparticipants [1] . This decrease is partly attributable to syringe exchange programs, which began in the early 1990s: the incidence of HIV infection among IDUs in NYC decreased from 4.4 cases per 100 person-years in 1992 [6] to ∼0.7 cases per 100 person-years in 1997 [7] . In 2001, injection drug use accounted for 1078 newly diagnosed HIV cases (26.7%) in NYC with a known risk factor, a steep decrease from the estimated rate of 50% in the early 1990s [8] . Nonetheless, syringe exchange coverage in NYC is limited to IDUs with access to one of the 9 legal programs, and IDU-related HIV transmission continues.
Expanding access to sterile syringes through other modalities is expected to further reduce the incidence of HIV infection. A survey of IDUs in Marseille, France, where IDUs obtain syringes through syringe exchange programs, pharmacies, and vending machines, found that each site attracted IDUs of different demographic characteristics, suggesting that multiple syringe sources increased the number of IDUs who obtained sterile syringes [9] . US government-funded studies conducted by the National Commission on AIDS [10] , the University of California [11] , the National Academy of Sciences [2] , and the Office for Technology Assessment [12] concluded that syringe clauses in drug paraphernalia laws and prescription requirements should be repealed or amended to increase access to sterile syringes among IDUs to help prevent bloodborne disease transmission. Although syringes provided through health care contacts may benefit a relatively small number of IDUs, this may have a substantial impact if those patients are already infected with HIV or hepatitis C virus. Moreover, such an intervention might attract IDUs into regular medical care and substance abuse treatment.
The Expanded Syringe Access Demonstration Program (ESAP), passed by the New York State legislature in 2000 and implemented on 1 January 2001, aimed to increase access to sterile syringes for IDUs. By registering with the State Department of Health, pharmacies were permitted to sell syringes without a prescription, and prescription-authorized health care providers were permitted to distribute syringes to patients without a prescription. In addition, ESAP aimed to improve syringe . In this study, we evaluated providers' knowledge of ESAP and their willingness to provide syringes to IDUs. We also compared the likelihood that providers would distribute syringes directly to patients or prescribe syringes to be picked up at a pharmacy. Methods. We obtained a list of all health care providers with prescription authority (nurse practitioners, physicians, and physician assistants) registered with the New York Department of Education through a Freedom of Information Act request. We limited nurse practitioners and physicians to a broad subset of medicine specialties addressing issues potentially related to patients' illicit drug use and drew a random sample of 1100 subjects. The sample was weighted to capture 70% physicians. Results. Twenty-nine surveys were undeliverable and 364 providers responded, for an overall response rate of 34.0%. A total of 363 responses were included in the analysis; 1 survey with missing data was excluded. As detailed in table 1, 54.0% of respondents were men, 68.4% were white, 13.6% were Asian or Pacific Islander, 9.4% were African American or black, and 5.8% were Latino. In accordance with our weighted sample, 15.6% of respondents were nurse practitioners, 68.0% were physicians, and 16.4% were physician assistants. Most respondents specialized in internal medicine (23.3%), psychiatry (17.5%), pediatrics (12.3%), and general practice (10.4%). More than one-third (39.6%) practiced in an office, 32.1% practiced in a hospital, 14.8% practiced in a clinic, and 2.5% practiced in other settings. ). P p .004 We evaluated agreement with several statements about providing syringes to IDUs. The following statements, suggestive of benefits of syringe provision, were positively associated with support for distributing or prescribing syringes: "providing syringes to IDUs is an important part of HIV/AIDS prevention" ( for distributing and prescribing syringes), "providing P ! .0001 syringes will decrease HIV transmission" ( for dis-P p .0017 tributing syringes and for prescribing syringes), and P ! .0001 "providers should distribute/prescribe syringes only if they also monitor and emphasize drug treatment" ( for dis-P p .0003 tributing syringes and for prescribing syringes). P p .0084 Other statements, which were suggestive of detrimental effects of syringe provision, were negatively associated with support for distributing or prescribing syringes: "it is not the role of providers to distribute/prescribe syringes" ( for dis-P ! .0001 tributing and providing syringes), "the community would be littered with syringes" ( for distributing and providing P ! .0001 syringes), "non-drug using patients would be uncomfortable" ( for distributing syringes and for providing P ! .0001 P p .0183 syringes), "the community would not support providing syringes" ( for distributing syringes and for pro-P ! .0001 P p .0056 viding syringes), and "providing syringes would increase drug use" ( for distributing syringes and for pro-P ! .0001 P p .0036 viding syringes).
Discussion. The New York State Department of Health focused on outreach to pharmacists to encourage participation in ESAP [14] and conducted relatively little outreach to the providers addressed in this survey. Given this minimal education, the limited awareness of ESAP is not surprising. Nonetheless, if one-half of providers offered syringes to injection drug using patients, as this study suggests may be feasible, the impact of this facet of ESAP on disease transmission could be substantial. Moreover, it is promising that many providers with injection drug using patients are aware of ESAP. Those respondents who would not consider distributing syringes generally had moral or ethical beliefs about drug use or concerns about the legality of the practice. Some were concerned that syringe distribution would increase the number of improperly discarded syringes; research on ESAP has demonstrated no such increase [15] .
Respondents may have been more supportive of syringe prescription than distribution because prescription is the traditional role of these providers. In a small survey of infectious disease and addiction medicine specialists in Rhode Island, 95% of respondents believed that IDUs had a legitimate medical need to obtain sterile syringes, and 71% would have prescribed syringes to IDUs for disease prevention if it were clearly legal to do so [16] . A case study of prescription of syringes to IDUs in Rhode Island has shown promise as an effective intervention [17] . On the basis of a 2002 analysis, prescription and pharmacy sale of syringes to IDUs with knowledge of the intent to use those syringes for illegal drug injection is clearly legal in New York State [18] . Future provider educational efforts should focus on clarifying the public health importance and explicit legality of furnishing IDUs with syringes through both distribution and prescription.
The response rate for this survey was low for epidemiologic research, but it was within the normal range for postal surveys and relatively high for postal surveys of this population. We compensated respondents in an attempt to minimize possible response bias associated with opinions and practices. Health care providers in New York and most other US states can legally prescribe syringes to IDUs for disease prevention. Through ESAP, the New York State legislature specifically permitted providers to also distribute syringes directed to IDUs. Additional education is needed to increase awareness of this new program and thereby improve access to sterile syringes for the prevention of bloodborne disease transmission.
